Clinical Trial Update: Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic and safety study evaluating Brivanib in Chinese patients with advanced hepatocellular carcinoma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Brivanib (brivanib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED